About Us
TWi USA
USA Team
Our Products
For Customers
Authorized Distributors
TWi USA State Licenses
Return Goods Policy
Customer Service Contacts
For Patients
Adverse Event Reporting, Product Complaints & Medical Information(FOr USA Only)
Sorafenib Co-Pay Savings Program
Contact Us
buPROPion Hydrochloride Extended-Release Tablets (XL)
Cyclobenzaprine Hydrochloride Extended-Release Capsules
Diltiazem Hydrochloride Extended-Release Capsules
Dimethyl Fumarate Delayed-Release Capsules
Donepezil tablets
Fenofibric Acid Delayed-Release Capsules
Fluphenazine Hydrochloride Tablets, USP
Guanfacine Hydrochloride Extended-Release Tablets
Hydroquinone Cream
MegestrolAcetate Oral Suspension
Metformin Hydrochloride Extended Release Tablets
Metoprolol Succinate Extended-Release Tablets
Mycophenolic Acid DR Tablets
Nifedipine Extended-Release tablets
Paclitaxel Protein-Bound Particles for Injectable Suspension - (Albumin-Bound)
Propafenone Hydrochloride Extended-Release Capsules, USP
Sevelamer Carbonate Tablets
Sorafenib Tablets, USP
Testosterone Gel, 1.62% CIII
Terbutaline Sulfate tablets
Testosterone Topical Solution CIII, USP
Home > Products > For the United States
Sevelamer Carbonate Tablets
Route
Oral
Dosage form
Tablets
Strength
800mg
Rx/OTC
Rx
Indication
Lower the amount of phospherous in patients receiving kidney dialysis.
TE Rating
AB
Reference Listed Drug
Renvela®
ANDA#
200959
Strength
Form
Product Description
Imprint
Image
How Supplied
NDC Number
HDMA
Sheets
PI
SDS
800mg
Tablets
Off white, modified oval tablet core, imprinted “T186” on one side and plain on the reverse side, film coated white
T186
Bottle of 270
24979-186-46
Back
Top